相关实验视频

Updated: Sep 8, 2025

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

立体体射线疗法加卡多尼利马布 (PD-1/CTLA-4双特异抗体) 作为第三线或超越治疗耐火固体瘤:一期1b研究

Yao Xiao¹, Yuxia Wang¹, Jun Li¹

¹Department of Radiation Oncology, Peking University Third Hospital, Beijing, P. R. China.

Cancer communications (London, England)

|July 22, 2025

概括

与cadonilimab结合的立体体射线疗法 (SBRT) 显示了可控的毒性和在先进的固体瘤中有希望的疗效. 这种组合疗法为严重预先治疗的患者提供了潜在的新治疗选择.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
辐射瘤学辐射瘤学

背景情况:

卡多尼利马布是一种针对PD-1和CTLA-4的新型双特异抗体.
先进的固体瘤往往对传统疗法具有抗性.
免疫疗法与放射治疗相结合是一种新兴的策略.

研究的目的:

为了评估SBRT与cadonilimab结合的安全性和有效性.
评估与治疗相关的不良事件 (TRAE) 和临床结果.
为了确定治疗反应的预测因素.

主要方法:

对63名患有晚期固体瘤的患者进行了回顾性研究.
用于高负担/症状性病变的SBRT.
静脉注射卡多尼利马布 (6毫克/公斤) 每隔两周一次.

主要成果:

目标响应率 (ORR) 为23.8% (95% CI,14.0%-36.2%). 目标响应率 (ORR) 是23.8% (95% CI,14.0%-36.2%). 目标响应率 (ORR) 是23.8% (95% CI,14.0%-36.2%). 目标响应率 (ORR) 是23.8% (95% CI,14.0%-36.2%). 目标响应率 (ORR) 是23.8%.
无进展生存时间 (PFS) 中位数为7.2个月;总生存时间 (OS) 中位数为10.0个月.
可管理的毒性,38.1%是TRAE,3.2%是3级.

结论:

SBRT加卡多尼利马布显示可控的毒性.
组合疗法在耐火实体瘤中显示出有希望的疗效.
需要在更大的试验中进行进一步的调查.

关键词:

卡多尼利马布 (Cadonilimab) 是一种免疫疗法免疫疗法耐火固体瘤耐火固体瘤在安全方面,安全是安全的.刻板印象的身体放射治疗.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...